Table 2 HTE reporting by study characteristics (n = 319 RCTs in 303 articles)
From: Dealing with heterogeneity of treatment effects: is the literature up to the challenge?
Characteristic | N | No. (%) Reporting HTE | No. (%) Reporting Either subgroup or HTE |
|---|---|---|---|
Journal of publication | †| †| |
   Annals | 30 | 11 (37) | 16 (53) |
   BMJ | 47 | 9 (19) | 18 (38) |
   JAMA | 50 | 21 (42) | 33 (66) |
   Lancet | 101 | 21 (21) | 53 (53) |
   NEJM | 91 | 30 (33) | 60 (66) |
Year of publication | |||
   1994 | 91 | 20 (22) | 47 (52) |
   1999 | 106 | 30 (28) | 62 (58) |
   2004 | 122 | 42 (34) | 71 (58) |
Medical condition under study | ‡ | ||
   Cardiovascular | 74 | 21 (28) | 43 (58) |
   Infectious disease | 70 | 25 (36) | 48 (69) |
   Cancer | 42 | 15 (36) | 30 (71) |
   Psychiatry/Neurology | 25 | 7 (28) | 12 (48) |
   Other | 108 | 24 (22) | 47 (44) |
First author's study region | ‡ | ‡ | |
   North America | 121 | 47 (39) | 80 (66) |
   Other | 198 | 45 (23) | 100 (51) |
Study design | ∥ | ||
   Parallel | 304 | 89 (29) | 177 (58) |
   Crossover | 15 | 3 (20) | 3 (20) |
Sample size | ** | ** | |
   Quintile 1 (median = 37) | 64 | 9 (14) | 18 (28) |
   Quintile 2 (median = 124) | 64 | 7 (11) | 29 (45) |
   Quintile 3 (median = 263) | 64 | 22 (34) | 45 (70) |
   Quintile 4 (median = 549) | 64 | 21 (33) | 40 (63) |
   Quintile 5 (median = 1560) | 63 | 33 (52) | 48 (76) |